Welcome!

News Feed Item

University of Maryland School of Medicine Scientist is at Forefront of Developing Vaccine for Ebola Virus

Alan Schmaljohn, Ph.D. has studied Ebola virus for decades through U.S. Army Medical Research Institute for Infectious Disease

BALTIMORE, Aug. 12, 2014 /PRNewswire-USNewswire/ -- As the number of lives taken by the Ebola virus in West Africa has surpassed 1,000, and the U.S. prepares as rapidly as it can, it is clear that little is known in the medical community about the virus. In fact, some experts point out that the number of medical professionals who can properly diagnose and recommend the next steps for treatment is alarmingly small.

Some scientists, however, like Alan Schmaljohn, Ph.D., Professor of Microbiology and Immunology at the University of Maryland School of Medicine (UM SOM), have spent decades studying the Ebola virus and similar viruses identifying key characteristics that have aided in the development of vaccines, antivirals and treatment methods.                                                                                         

As a leader of research and Chief in the Viral pathogenesis and Immunology Branch with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Dr. Schmaljohn was able to help identify three of the key antibodies that are used currently in combination with each other to treat patients infected with Ebola.

Dr. Schmaljohn is now one of the scientific leaders in the UM SOM partnership with Department of Defense contract recipient Paragon Bioservices in the manufacture of an Ebola virus vaccine for initial safety testing in humans.

"Several vaccine candidates for Ebolavirus are proceeding through initial manufacture toward safety testing in human volunteers," Dr. Schmaljohn said.  "Different vaccine candidates are based upon different 'platforms' in which selected viral proteins may be made 'in the test tube' and purified for injection, or may be added genetically as passengers of a different variety of virus that is weakened. Only human trials will provide the final answers as to which vaccines are best on the basis of many criteria, foremost being safety and efficacy," he said.

Dr. Schmaljohn was originally one of the leaders in determining what kinds of immune responses are required for protection against viruses like Ebola and he was part of the team that first identified antibodies capable of protecting certain animals from Ebola virus.  "Subsequently," he said, "three of these antibodies have been developed as a candidate mixture for human therapy against Ebolavirus, which seems to be true with an American who was infected with Ebolavirus during the current outbreak."  However, he cautions that many scientific questions remain unanswered. 

E. Albert Reece, M.D., Ph.D., M.B.A., Vice President of Medical Affairs at the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor and Dean of the UM SOM, said, "We are grateful to have scientists at the UM SOM like Dr. Schmaljohn who have studied viruses like Ebola for decades.  We can now build on that knowledge and understanding to focus on bridging the science to the development of new vaccines.  The University of Maryland School of Medicine is well-positioned to play an integral role in addressing this serious public health issue."

The UM SOM has been an international leader in both vaccine development and study of infectious disease for many years with longstanding support from NIH and other federal agencies.

Scientists in the School's Department of Microbiology and Immunology, under the leadership of James B. Kaper, Ph.D, have opened new approaches to the basic and applied aspects of infectious diseases and host defenses.  They are applying these approaches to basic aspects of receptor signaling, regulation of gene expression in both prokaryotic and eukaryotic cells and interactions between these cells, genetic manipulation of cellular functions, microbial genomics and evolution, and development of new vaccination strategies. The techniques of functional genomics, gene delivery, stem cells and transgenic/gene disruption animal models are being developed to address specific questions.

The pioneering work of the UM SOM's Center for Vaccine Development, under Myron Levine, M.D., D.T.P.H., founded the discipline now known as "vaccinology," which incorporates measurement of the burden of a disease to direct vaccine research; construction of vaccine candidates; clinical trials to demonstrate the safety of a vaccine and its ability to stimulate immune responses and to protect against disease; and documentation of the public health impact that follows introduction of the vaccine into widespread use.  The earliest NIH-supported formal training programs in the field of vaccinology were established by Dr. Levine at the SOM.  It was, and still is, funded with a T32 Grant from the National Institutes of Health (NIH). Dr. Levine has also oriented the discipline at Maryland to address the development and introduction of vaccines to prevent diseases afflicting impoverished populations in the developing world.

The UM SOM is also home to the Institute of Human Virology (IHV) under the leadership of Robert C. Gallo, M.D.  The IHV is the first center in the U.S. to combine the disciplines of basic science, epidemiology and clinical research in a concerted effort to speed the discovery of diagnostics and therapeutics for a wide variety of chronic and deadly viral and immune disorders, most notably HIV.  Dr. Gallo, who is widely known for his pioneering research in the field of human retroviruses with his discoveries of, Il-2, HTLV-1 and HTLV-2, his co-discovery of HIV as the cause of AIDS, and his development of the HIV blood test, is The Homer & Martha Gudelsky Distinguished Professor of Medicine and Director of the Institute of Human Virology in the School of Medicine, and Co-Founder and Scientific Director of the Global Virus Network (GVN).

CONTACT: Christopher Hardwick[email protected]

SOURCE University of Maryland School of Medicine

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Things are changing so quickly in IoT that it would take a wizard to predict which ecosystem will gain the most traction. In order for IoT to reach its potential, smart devices must be able to work together. Today, there are a slew of interoperability standards being promoted by big names to make this happen: HomeKit, Brillo and Alljoyn. In his session at @ThingsExpo, Adam Justice, vice president and general manager of Grid Connect, will review what happens when smart devices don’t work togethe...
Building a cross-cloud operational model can be a daunting task. Per-cloud silos are not the answer, but neither is a fully generic abstraction plane that strips out capabilities unique to a particular provider. In his session at 20th Cloud Expo, Chris Wolf, VP & Chief Technology Officer, Global Field & Industry at VMware, will discuss how successful organizations approach cloud operations and management, with insights into where operations should be centralized and when it’s best to decentraliz...
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
Deep learning has been very successful in social sciences and specially areas where there is a lot of data. Trading is another field that can be viewed as social science with a lot of data. With the advent of Deep Learning and Big Data technologies for efficient computation, we are finally able to use the same methods in investment management as we would in face recognition or in making chat-bots. In his session at 20th Cloud Expo, Gaurav Chakravorty, co-founder and Head of Strategy Development ...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
Imagine having the ability to leverage all of your current technology and to be able to compose it into one resource pool. Now imagine, as your business grows, not having to deploy a complete new appliance to scale your infrastructure. Also imagine a true multi-cloud capability that allows live migration without any modification between cloud environments regardless of whether that cloud is your private cloud or your public AWS, Azure or Google instance. Now think of a world that is not locked i...
Technology innovation is the driving force behind modern business and enterprises must respond by increasing the speed and efficiency of software delivery. The challenge is that existing enterprise applications are expensive to develop and difficult to modernize. This often results in what Gartner calls "Bimodal IT," where business struggle to apply modern tools and practices to traditional monolithic applications. But these existing assets can be modernized and made more efficient without havin...
Most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes a lot of work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reduction in cost...
SYS-CON Events announced today that CA Technologies has been named “Platinum Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business – from apparel to energy – is being rewritten by software. From ...
SYS-CON Events announced today that Auditwerx will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Auditwerx specializes in SOC 1, SOC 2, and SOC 3 attestation services throughout the U.S. and Canada. As a division of Carr, Riggs & Ingram (CRI), one of the top 20 largest CPA firms nationally, you can expect the resources, skills, and experience of a much larger firm combined with the accessibility and attent...
SYS-CON Events announced today that Technologic Systems Inc., an embedded systems solutions company, will exhibit at SYS-CON's @ThingsExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Technologic Systems is an embedded systems company with headquarters in Fountain Hills, Arizona. They have been in business for 32 years, helping more than 8,000 OEM customers and building over a hundred COTS products that have never been discontinued. Technologic Systems’ pr...
SYS-CON Events announced today that HTBase will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. HTBase (Gartner 2016 Cool Vendor) delivers a Composable IT infrastructure solution architected for agility and increased efficiency. It turns compute, storage, and fabric into fluid pools of resources that are easily composed and re-composed to meet each application’s needs. With HTBase, companies can quickly prov...
SYS-CON Events announced today that Loom Systems will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2015, Loom Systems delivers an advanced AI solution to predict and prevent problems in the digital business. Loom stands alone in the industry as an AI analysis platform requiring no prior math knowledge from operators, leveraging the existing staff to succeed in the digital era. With offices in S...
In his session at Cloud Expo, Alan Winters, an entertainment executive/TV producer turned serial entrepreneur, will present a success story of an entrepreneur who has both suffered through and benefited from offshore development across multiple businesses: The smart choice, or how to select the right offshore development partner Warning signs, or how to minimize chances of making the wrong choice Collaboration, or how to establish the most effective work processes Budget control, or how to max...